Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
University College Hospital, Ibadan, Nigeria
department of anesthesiology, Bichat Hospital, Paris, France
department of anaesthesiology, CHU Jean Minjoz, Besancon, France
Hopital Foch, Suresnes, France
Khon Kaen Regional hospital, Muang district, Khon Kaen, Thailand
Department of Obstetrics and Gynecology, Kalmar Central Hospital, Kalmar, Sweden
Dept of Obstetric and Gynecology, Ryhov Central Hospital, Jönköping, Sweden
University Hospital, Department of Obsterics and Gynecology,, Linköping, Sweden
The Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Rockyview General Hospital, Calgary, Alberta, Canada
Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia, Milano, Italy
Università degli Studi di Milano, Dipartimento di Medicina Interna, Milano, Italy
Trillium Health Centre, Mississauga, Ontario, Canada
Department of Anesthesia and Orthopedics; Toronto Western Hospital, Toronto, Ontario, Canada
St. Michael's Hospital, Toronto, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.